Still High, Not Impaired — Why THC in Your Blood Isn’t Proof You Shouldn’t Have Been Driving
Here is a fact that surprises most people: a person can test positive for THC in their blood hours after any impairing effect has worn off. Another fact, equally surprising: a chronic cannabis user can have blood THC levels that would suggest significant impairment in an occasional user — and yet show no meaningful degradation in driving-relevant cognitive or motor skills. And a third: a urine test that comes back positive for cannabis metabolites tells you almost nothing reliable about whether someone was impaired while driving, because those metabolites can linger in the body for weeks after the last use.
These are not arguments for impaired driving. They are statements of pharmacological fact — and they sit at the heart of one of the most contested areas in forensic toxicology today. As cannabis legalization expands across the United States and around the world, the question of how to reliably detect and prosecute cannabis-impaired driving has become urgent. The honest answer, supported by a substantial body of research, is that blood THC levels alone are a poor proxy for impairment. Understanding why requires a closer look at what THC actually does inside the human body.
The Molecule That Hides in Fat
To understand why THC behaves so differently from alcohol in forensic testing, one fact about its chemistry is essential: THC is highly lipophilic. It dissolves readily in fat, not in water. Alcohol, by contrast, is water-soluble — it distributes evenly through the body’s water-based fluids, including blood, and leaves at a predictable, measurable rate. THC does something fundamentally different.
Within minutes of inhalation, THC enters the bloodstream and produces its psychoactive effects — but almost immediately, it begins moving out of the blood and into fatty tissues throughout the body: the brain, adipose tissue, organs. Blood THC concentrations can fall by 80 to 90 percent within an hour of smoking, not because the drug has left the body, but because it has redistributed into fat. It then seeps back out of those tissues slowly, over days or weeks, in amounts too small to produce psychoactive effects but large enough to remain chemically detectable.
This redistribution dynamic — rapid absorption, rapid initial drop, prolonged slow release — is the source of almost every controversy surrounding cannabis testing. It means that the relationship between what a blood test measures and what a person is actually experiencing at any given moment is far less direct than it is with alcohol.
What Happens After You Consume Cannabis
The pharmacokinetic profile of THC varies significantly depending on how it is consumed. This matters because the route of consumption affects how quickly THC enters the bloodstream, when it peaks, and how long it takes to fall below practically impairing levels.
| Consumption Method | Onset of Effects | Peak Blood THC | Subjective Effects Duration | Blood THC Detectable |
|---|---|---|---|---|
| Smoked / vaped | Seconds to minutes | Within 10–30 minutes | 1–3 hours | Up to 12–24 hours (occasional users); longer in chronic users |
| Oral (edibles) | 30 minutes to 2 hours | 1–3 hours after ingestion | 4–8 hours | Up to 24–48 hours |
| Sublingual (tinctures) | 15–45 minutes | Variable | 2–4 hours | Variable; similar to oral |
Two aspects of this table are worth dwelling on. First, blood THC is already declining steeply while subjective effects are still being felt after inhalation — meaning a test taken shortly after use may show a falling concentration even when impairment is still present. Second, and more consequentially for law enforcement, blood THC can remain detectable for many hours after all practically impairing effects have subsided — particularly in frequent users whose fat stores have accumulated THC over time.
Blood vs. Urine: What Each Test Actually Tells You
Most drug tests in non-driving contexts — workplace testing, probation compliance monitoring, pre-employment screening — use urine. In driving impairment cases, blood is the preferred specimen because it more directly reflects what is circulating in the body at the time of testing. But neither test provides a straightforward answer to the question that actually matters in a DUID case: was this person impaired while driving?
| Test Type | What It Detects | Detection Window | What It Proves About Impairment |
|---|---|---|---|
| Blood THC (parent compound) | Active THC circulating in blood | Hours to ~24 hours (occasional); days in chronic users | Recent use likely; impairment possible but not established |
| Blood 11-OH-THC | Active metabolite; significant with edibles | Hours | Recent use; also psychoactive but concentration-impairment link uncertain |
| Blood THC-COOH | Inactive metabolite | Days to weeks | Prior exposure; essentially nothing about current impairment |
| Urine THC-COOH | Inactive metabolite | 3–30+ days depending on use frequency | Cannabis was used at some point; nothing about impairment timing |
The distinction between THC and THC-COOH is critical and frequently misunderstood. THC-COOH — the metabolite most commonly detected in urine screening — is pharmacologically inactive. It does not cause impairment. Its presence means cannabis was consumed within the detection window, which could be last night or three weeks ago. Using a positive urine THC-COOH result as evidence of driving impairment is scientifically indefensible — yet this conflation happens regularly in legal proceedings involving untrained fact-finders.
The Chronic User Problem
Even blood THC — the most relevant of the available measurements — loses much of its interpretive value in frequent cannabis users. This is one of the most well-documented and most inconvenient findings in the cannabis pharmacology literature.
Chronic cannabis users accumulate THC in fat tissue over time. As a result, THC continuously seeps back into the bloodstream in small amounts, meaning that a daily user may have measurable blood THC levels upon waking in the morning — before any use that day — simply from the slow release of previously stored drug. Studies have documented blood THC concentrations of 2 to 5 ng/mL in chronic users who have abstained from cannabis for 24 hours or more. At the same concentrations, an occasional user might show meaningful impairment. The chronic user, having developed substantial tolerance, may be functionally unimpaired.
This tolerance effect is not unique to cannabis — it occurs with alcohol and many other substances — but it is particularly pronounced with THC because of the fat-storage dynamic. The practical implication is significant: in a chronic user, a blood THC reading tells you even less about current impairment than it does in an occasional user.
What the Driving Research Actually Shows
A substantial body of research has examined the relationship between blood THC levels and actual driving performance, using both driving simulators and instrumented on-road studies. The findings are genuinely mixed — which is itself an important conclusion.
Cannabis does impair driving. That baseline finding is consistent across the research literature. Acutely intoxicated users — particularly those who are occasional consumers and have recently smoked at moderate to high doses — show measurable degradation in lane-keeping, reaction time, and speed regulation. The impairment is real.
But the dose-response relationship between blood THC and driving performance is weak, especially compared to alcohol. Key findings from the research include:
- A large-scale naturalistic driving study by the National Highway Traffic Safety Administration found that cannabis use was associated with a statistically significant increase in crash risk — but that when researchers controlled for age and gender, the elevated risk largely disappeared, suggesting that the association may have more to do with the demographics of cannabis users than with THC impairment itself.
- Studies using driving simulators consistently find that impairment is most pronounced in the first one to two hours after smoking and at higher doses, and diminishes substantially thereafter — while blood THC may still be detectable.
- Experienced cannabis users consistently outperform occasional users on driving tasks at the same blood THC concentrations, demonstrating that tolerance substantially modifies the impairment that any given concentration produces.
- Unlike alcohol, for which the impairing effects tend to be underestimated by the user, cannabis users tend to be aware of their impairment and compensate behaviorally — slowing down, increasing following distance, avoiding risky maneuvers. This compensatory behavior does not eliminate impairment but partially offsets it in ways that have no equivalent in alcohol-impaired driving.
The Per Se Limit Problem
Several U.S. states — including Washington, Colorado, Montana, and Nevada — have adopted per se THC limits, most commonly set at 5 nanograms per milliliter of THC in whole blood. The intent mirrors the 0.08% BAC standard for alcohol: establish a threshold above which impairment is legally presumed.
The scientific community has been largely critical of this approach. The core objection is straightforward: unlike the 0.08% BAC standard, which is grounded in decades of research showing a consistent population-level relationship between that concentration and impaired driving, no equivalent evidence base supports 5 ng/mL THC as a reliable impairment threshold. The American Automobile Association (AAA) Foundation for Traffic Safety concluded in a widely cited 2016 report that a valid, evidence-based threshold for per se DUID cannabis laws does not exist — and that such limits risk convicting unimpaired drivers while allowing impaired ones to escape prosecution if their blood THC happens to fall below the cutoff.
The 5 ng/mL figure was not derived from impairment research. It emerged largely as a pragmatic legal compromise in the context of early cannabis legalization — a number that seemed reasonable rather than one demonstrably tied to a level of impairment that affects driving safety. Most forensic toxicologists and pharmacologists who study this area regard it as scientifically arbitrary.
What Actually Establishes Cannabis Impairment
If blood THC levels alone are insufficient, what does establish cannabis impairment in a legally and scientifically sound way? The answer is converging evidence from multiple sources — none of which is individually definitive, but which together build a stronger case than any single measurement:
- Observed driving behavior — lane weaving, inappropriate speed, delayed reactions at signals, documented by the officer and ideally captured on dash or body camera
- Physical observations at the stop — bloodshot eyes, the odor of cannabis, slowed speech, impaired coordination, disorientation
- SFST performance — particularly divided attention tests, which cannabis impairs more reliably than balance tests at typical recreational doses
- DRE evaluation findings — including elevated pulse, reddened conjunctiva, rebound pupil dilation, and the DRE officer’s categorical opinion
- Blood THC interpreted in context — a forensic toxicologist’s opinion on what the measured concentration means given the timing of the blood draw, the subject’s apparent use history, and the other evidence in the case
Conclusion
The science of THC and driving impairment is genuinely complicated — not because researchers have failed to study it, but because the drug itself behaves in ways that resist simple measurement. Its fat-solubility, the tolerance it produces in frequent users, the gap between detectable presence and impairing effect, and the weakness of the concentration-impairment relationship all conspire to make THC a poor candidate for the kind of bright-line threshold testing that has served alcohol enforcement so well. That does not mean cannabis-impaired driving is undetectable or unprosecutable — it means that detecting and proving it requires more than a number on a toxicology report. It requires the kind of holistic, evidence-based assessment that trained investigators, forensic toxicologists, and courts are slowly developing the tools to perform. Until a validated, evidence-based impairment threshold exists for THC, that work will remain harder, more contested, and more dependent on expert interpretation than anyone involved would prefer.